rat anti mouse cd4  (Bio-Rad)

Journal: FASEB BioAdvances

Article Title: The Impact of Heterotopic Spleen Regeneration on Tumor Growth

doi: 10.1096/fba.2025-00254

Figure Lengend Snippet: Analysis of cell population in tumor of intact, SE and SE+ST animals on Days 7 (A), 12 (B) and 15 (C). Blue arrows—gating from CD3+ cell population, green arrows—gating from CD3− cell population. D, Percentage content of CD3+, CD8a+, CD4+, CD45R+, F4/80+Ly6C−, F4/80−Ly6C+, F4/80+Ly6C+ cells. (A–D) N = 3 per group. Statistical analysis was carried out by non‐parametric Kruskal–Wallis test with post hoc Dunn's test (mean with SEM), * р ‐value ≤ 0.05, ** p ‐value ≤ 0.005, *** p ‐value ≤ 0.0005.

Article Snippet: To determine the phenotypes of tumor‐infiltrating cells, isolated cells were stained for 1 h at room temperature in the dark with the following panel of anti‐mouse antibodies: CD8a antibody anti‐mouse VioBlue (130‐123‐865, Miltenyi Biotec, Germany), CD3 antibody anti‐mouse FITC, REAfinity (130‐119‐758, Miltenyi Biotec, Germany), F4/80‐PE REAfinity (130‐102‐422, Miltenyi Biotec, Germany), rat anti‐mouse CD4 StarBright Blue 700 (SBB700) (MCA2691SBB700, Biorad, USA), CD45R antibody anti‐mouse PE‐Vio 770 (130‐102‐817, Miltenyi Biotec, Germany), Ly‐6C antibody anti‐mouse APC REAfinity (130‐111‐779, Miltenyi Biotec, Germany).

Techniques:

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: Immunogenicity of Als3p/Hyr1p dual antigen vaccine formulated with alum, CAF01, or BDX100 adjuvants. (A). Combination of Als3p/Hyr1p doses by checkerboard method. (B). Schematic of the experimental design for determining vaccine-induced immunogenicity is shown. The ICR CD-1 mice ( N = 5/group) vaccinated SC (Alum, CAF01) or IN (BDX100) with different vaccine formulations (Als3p and Hyr1p antigens ratio on the x-axis) on days 0 and 21. Two weeks after the final vaccination, serum antigen-specific IgG titers and T cells were evaluated using ELISA and FluroSpot assay, respectively. Comparison of (C). Anti-Als3p and (D). anti-Hyr1p IgG endpoint titers in alum, CAF01 or BDX100 adjuvant-antigen formulations. Anti-Als3p and anti-Hyr1p IgG endpoint titers in (E). alum, (F). CAF01, (G). BDX100 adjuvant-antigen formulations. (H). Heat map showing the mean frequency ( n = 5 mice/cell/formulation) of Als3p or Hyr1p-specific Th1, Th2, and Th17 cells (IFN- γ, IL-4 or IL17 producing cells) in mice vaccinated with alum, CAF01 or BDX100 vaccine formulations. Each row represents data from each vaccine formulation. (I). Bar graph showing Als3p or Hyr1p-specific Th1, Th2, and Th17 cells.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Flurospot, Comparison, Adjuvant, Formulation

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: Mechanism of VXV-01-mediated protection. Naïve mice or vaccinated mice ( n = 10 mice/group) were infected with C. albicans or C. auris . For vaccination, the VXV-01 or placebo (adjuvant only) was administered on days 0, 21, and 35 (for C. albicans infection) or days 0 and 21 (for C. auris infection). Mice were immunosuppressed with cyclophosphamide and cortisone acetate for C. auris infection. Naïve mice ( n = 10 mice/group) infected with (A). C. albicans or (C). C. auris received two intraperitoneal anti-sera injections at 2 and 168 h relative to infection. Vaccinated mice ( n = 10 mice/group) received anti-CD4 or isotype control antibodies to deplete the CD T cells. The mice were infected with (B). C. albicans or (D). C. auris . Mice survivals were compared by Mantel-Cox test, and p < 0.5 was considered statistically significant.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Infection, Adjuvant, Control

Journal: Scientific Reports

Article Title: Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

doi: 10.1038/s41598-025-32488-8

Figure Lengend Snippet: The durability of VXV-01 vaccine-induced immunity. The ICR (CD-1) mice were vaccinated sub-cutaneously with VXV-01 or placebo (adjuvant alone) on days: (A). 0, 21; or (B). 0, 21, 35. The serum anti-Als3p and anti-Hyr1p IgG endpoint titers and T cells were evaluated using ELISA and FluroSpot assay on days 14, 28, 90, 180, and 270 post-final vaccination. ( C ). Anti-Als3p, and ( D ). Hyr1p IgG endpoint titers and T-cell responses were compared between two and three vaccination schedules over the period of 270 days post-vaccination. Data presented as mean ± SE of N = 5 mice/group. ( E ). VXV-01 efficacy was tested after 15 weeks of final two doses vaccination regimen (day 0, 21) against C. auris infection in immunosuppressed mice ( N = 10 mice/group). Survival curves were compared by the Mantel-Cox test, and p < 0.5 was considered statistically significant.

Article Snippet: For CD4 + T cell depletion, 200 μg/mouse dose of rat anti-mouse CD4 IgG2b (clone GK1.5, BioXcell, Cat #BE0003-1)) or rat IgG2b isotype antibodies (Clone: LTF-2, BioXcell, Cat #BE0090) were administered intraperitoneally on day − 3 and 0 relative to infection.

Techniques: Adjuvant, Enzyme-linked Immunosorbent Assay, Flurospot, Infection